Lysine acetylation of TDP-43 drives phase separation and pathological aggregation

Jorge Garcia Morato[1,2], Friederike Hans[1,2], Felix von Zweydorf[2], Regina Feederle[3,4], Simon J. Elsässer[5], Angelos A. Skodras[6], Christian Johannes Gloeckner[2,7], Manuela Neumann[2,8], Philipp J. Kahle[1,2,*]

[1] Laboratory of Functional Neurogenetics, Department of Neurodegeneration, Hertie Institute for Clinical Brain Research, University of Tübingen, 72076 Tübingen, Germany

[2] German Center for Neurodegenerative Diseases (DZNE), 72076 Tübingen, Germany

[3] Institute for Diabetes and Obesity, Monoclonal Antibody Core Facility and Research Group, Helmholtz Zentrum München, 85764 Neuherberg, Germany

[4] German Center for Neurodegenerative Diseases (DZNE), 81377 München, Germany

[5] Science for Life Laboratory, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, 17165 Stockholm, Sweden

[6] Molecular Imaging Unit, Department of Cellular Neurology, Hertie Institute for Clinical Brain Research, University of Tübingen, 72076 Tübingen, Germany

[7] University of Tübingen, Center for Ophthalmology, Institute for Ophthalmic Research, 72076, Tübingen, Germany

[8] Department of Neuropathology, University Hospital, 72076 Tübingen, Germany

* Corresponding author. Tel: +49 7071 29-81970; E-mail: philipp.kahle@uni-tuebingen.de

Abstract

The trans-activation response DNA-binding protein TDP-43 regulates RNA processing and forms neuropathological aggregates in patients with amyotrophic lateral sclerosis and frontotemporal lobar degeneration. Investigating TDP-43 post-translational modifications, we discovered that K84 acetylation reduced nuclear import whereas K136 acetylation impaired RNA binding and splicing capabilities of TDP-43. Such failure of RNA interaction triggered TDP-43 phase separation mediated by the C-terminal low complexity domain, leading to the formation of insoluble aggregates with pathologically phosphorylated and ubiquitinated TDP-43. Confirming the results from site-directed mutagenesis, we succeeded to introduce authentic acetyl-lysine at the identified sites via amber suppression. [AcK84]TDP-43 showed cytoplasmic mislocalization and the aggregation propensity of [acK136]TDP-43 was confirmed. With newly developed antibodies, we found that the nuclear sirtuin SIRT1 can potently deacetylate [acK136]TDP-43. Moreover, SIRT1 reduced the aggregation propensity of [acK136]TDP-43. Thus, distinct lysine acetylations modulate nuclear import, RNA binding and phase separation of TDP-43, suggesting novel regulatory mechanisms for TDP-43 pathogenesis.

Introduction

The trans-activation response DNA-binding protein of 43kDa (TDP-43) regulates various RNA processing steps[1-3] and is found in the neuropathological lesions of patients with amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD)[4,5]. The TDP-43 polypeptide contains two RNA recognition motifs (RRM1 and RRM2), a nuclear localisation signal (NLS) and a C-terminal glycine-rich low complexity domain (see Fig. 1a). The NLS allows active nuclear import[6], but TDP-43 can also shuttle between the nucleus and cytoplasm[7]. Through its RRMs TDP-43 binds to UG-rich regions of RNA[8] and it is involved in RNA transport, stability, and splicing, for example exon 9 of the cystic fibrosis transmembrane conductance regulator (*CFTR*) mRNA[9]. The C-terminal low complexity domain of TDP-43 promotes liquid-liquid phase separation (LLPS) as well as pathological protein aggregation[10]. Post-translational

modifications (PTMs) can modulate TDP-43 functions in health and disease[11]. Putative pathological PTMs of TDP-43 include C-terminal fragmentations and phosphorylations[12], including the widely used marker pS409/410[13,14]. In addition lysine modifications have been reported, including ubiquitinations at various residues[15] and sumoylation and acetylation of the RRM1[16,17]. The putative acetyl-mimic [K145Q]TDP-43 was distributed in a stippled manner in transfected cells, eventually recapitulating pathological phosphorylation and recruitment of ALS-related factors into TDP-43 aggregates[18]. In addition, [K145Q]TDP-43 had reduced *CFTR* splicing activity. Thus, lysine modifications may be important for physiology and pathological aggregation of TDP-43. However, the genesis of TDP-43 aggregates remains elusive.

New research on LLPS is unveiling the molecular processes regulating the arrangement of membrane-less organelles. Heteronuclear ribonucleoprotein (hnRNP) LLPS is amply reported but whether and how this process is regulated in cells is poorly understood[19]. In the case of TDP-43, RNA binding prevents its phase separation *in vitro* and reduces droplet formation *in vivo*[20]. Wild-type (wt)TDP-43 is capable of going into liquid droplets but pathological mutants seem to form more resilient droplets. While the C-terminal glycine-rich domain of TDP-43 seems to play a crucial role in the formation of phase-separated droplets[21], the N-terminal domain may also contribute to the aggregation process[22-24]. Thus, the regulation of TDP-43 RNA binding could be pivotal in the pathophysiology of TDP-43. The molecular pathways regulating the disengagement from RNA are only beginning to be described.

In the present study we discovered that acetylation of K84 within the NLS reduced nuclear import whereas acetylation of K136 in the RNA recognition domain impaired TDP-43 RNA binding and splicing capabilities. Such failure of RNA interaction triggered TDP-43 phase separation mediated by the C-terminal low complexity domain[25], leading to the formation of insoluble aggregates with pathologically phosphorylated and ubiquitinated TDP-43. To confirm the results from site-directed mutagenesis, we expanded the genetic code via amber suppression[26] to introduce authentic acetyl-lysine at the identified sites. Indeed, [acK84]TDP-43 showed cytoplasmic mislocalization, and the increased aggregation tendency for [acK136]TDP-43 was confirmed. With newly developed antibodies, we found that the

nuclear sirtuin SIRT1 can potently deacetylate [acK136]TDP-43. Moreover, SIRT1 reduced the aggregation propensity of [acK136]TDP-43. Thus, distinct lysine acetylations regulate nuclear import, RNA binding and phase separation of TDP-43, suggesting novel mechanisms for TDP-43 pathogenesis.

Results

Detection of TDP-43 acetylation

While investigating the sites of TDP-43 lysine ubiquitinations[15], we detected in the mass spectrometry (MS) measurements another lysine modification, namely acetylation (Supplementary Table 1). In transfected HEK293E cells, 6xHis-tagged wtTDP-43 was acetylated at lysine residues K79 and K84 around the NLS and K121 and K136 in RRM1 (Fig. 1a). We could not detect the previously published acetylations at K145 and K192[17], perhaps due to slight differences in experimental conditions (see discussion).

Site-directed mutagenesis of TDP-43 acetyl-lysine sites

Each of the identified acetylated lysine residues was mutagenized to either arginine or glutamine to simulate the lack or the presence of acetylation, respectively. We first looked at the subcellular distribution of these N-terminally 6xHis-tagged TDP-43 mutants in transiently transfected HEK293E cells. Immunofluorescence staining of the 6xHis tag did not show visible deviation from the wtTDP-43 nuclear staining pattern for both acetyl-dead and acetyl-mimic mutations at residues K79 and K121 (Supplementary Fig. 1). Likewise, the conservative [K84R]TDP-43 mutant remained mainly nuclear, but a substantial portion of acetyl-mimic [K84Q]TDP-43 was retained in the cytoplasm (Fig. 1b). Quantification showed a significant reduction of nuclear import for [K84Q]TDP-43 (Fig. 1c). In addition, we performed biochemical nuclear-cytoplasmic fractionation assays. There was an obvious increase of [K84Q]TDP-43 in the cytoplasmic fraction and concomitant reduction in the nuclear fraction when compared to wtTDP-43 (Fig. 1d). Nevertheless, we could still observe a sizable amount of [K84Q]TDP-43 in the nuclear fraction in

the biochemical assay (compare Fig. 1d with Fig. 1b). Thus, acetylation of K84 partially reduced nuclear import of TDP-43 whereas the acetyl-mimic K79Q substitution did not show evident changes in nucleocytoplasmic distribution of TDP-43, likely because K79 is localized just outside the NLS, whereas K84 is at the core of the NLS[6,15].

The RRM1 mutants K136R and K136Q were predominantly localized in the nucleus, but a significant number of cells displayed a droplet-like pattern of nuclear aggregates (Fig. 1b,c). This droplet-like nuclear distribution was reminiscent of the RNA-binding deficient F147L/F149L mutant TDP-43[27]. For comparison, we generated the previously described[17,18] acetyl-mimic K145Q mutant in RRM1, which showed the expected stippled distribution (Fig. 1b). As K136 is in direct contact with bound nucleic acids[28,29], we assume that modifications at K136 disrupt nucleic acid binding and therefore disengage TDP-43 from hnRNP complex localizations. Such dissociated K136-modified TDP-43 may be free to self-aggregate into inclusions.

K136 mutant TDP-43 is pathologically ubiquitinated, phosphorylated, and insoluble

We examined if the K136 mutant TDP-43 inclusions in cell culture also showed pathological features described for human patients[4,5,13,30]. 6xHis-tagged TDP-43 variants were transiently transfected into HEK293E cells with stable knockdown of endogenous TDP-43 (sh^{TDP-43})[31] to minimize interference from the endogenous wtTDP-43. To assess protein solubility, RIPA-urea solubility fractionation assays were performed. While most of the 6xHis-tagged wtTDP-43 was RIPA-soluble, a larger portion of both K136R and K136Q TDP-43 mutants shifted into the RIPA-insoluble fraction (Fig. 2a). Although [F147L/F149L]TDP-43 formed similar intranuclear patches[27], this designed RNA-binding deficient mutant was as soluble as endogenous TDP-43 (Fig. 2a). It should be noted that the Flag-tagged [F147L/F149L]TDP-43 was expressed at levels comparable to endogenous TDP-43 in non-silenced cells, whereas the 6xHis-tagged K136 mutants were expressed at higher levels.

To check for pathological PTMs, 6xHis-tagged TDP-43 variants were transiently transfected into sh^{TDP-43}-HEK293E cells and purified using nickel beads. Both K136R and K136Q TDP-43 were ubiquitinated more strongly than wtTDP-43 even after proteasomal inhibition (Fig. 2b). In addition, K136R and K136Q mutant TDP-43 showed phosphorylation at the extreme C-terminal serine residues S409/410 detected with a phospho-specific antibody[14] (Fig 2b). This pathological phosphorylation was also visible at the nuclear inclusions of K136 mutant TDP-43 by immunostaining (Fig. 2c). Thus, the nuclear inclusions formed by K136 mutant TDP-43 recapitulate PTMs found in patients.

K136 mutant TDP-43 fails to bind RNA and lacks splicing activity

Because K136 in the RRM1 is important for interaction with nucleic acids[28,29], we hypothesised that alterations at position K136 could interfere with RNA binding of TDP-43 and alter its splicing capabilities. First, we performed a RNA-protein pulldown assay of TDP-43 with its preferred binding sequence poly-$(UG)_{12}$[32]. While wtTDP-43 strongly bound to synthetic poly-$(UG)_{12}$ but not the negative control poly-$(UC)_{12}$ RNA, the acetyl-mimic [K136Q]TDP-43 showed a reduction in RNA binding (Fig. 2d). To assess the splicing activity of TDP-43 in cells, we used the established *CFTR* minigene reporter assay[9]. To minimize the splicing activity of the endogenous wtTDP-43, we used sh^{TDP-43}-HEK293E cells[31]. Mutant constructs of TDP-43 were co-transfected together with a plasmid containing exons 9-11 of *CFTR* in a minigene. In parental, non-silenced cells ex9 was skipped, which was severely blunted in sh^{TDP-43} cells (Fig. 2e). Ex9 splicing could be rescued by re-transfecting wtTDP-43 (Fig. 2e). The nuclear [K84R]TDP-43 rescued *CFTR* splicing to wild-type levels. Interestingly, [K84Q]TDP-43 also rescued *CFTR* splicing activity (Fig. 2e), suggesting that the residual nuclear [K84Q]TDP-43 (Fig. 1d) was sufficient to promote ex9 skipping. Indeed, in our experience very strong reduction of TDP-43 activity is necessary to cause loss of TDP-43 splice activity in cells. In contrast, both K136R and K136Q mutants showed significantly reduced *CFTR* exon 9 splicing (Fig. 2e,f), linking the formation of nuclear aggregates with TDP-43 loss of function. The previously described[17,18] K145Q mutant TDP-43 also showed some reduction of *CFTR* splice activity,

although the effect was not as strong as for the K136 mutants expressed at comparably high protein levels (Fig. 2e). Together, both *CFTR* splicing assay and RNA-protein pulldown show that alterations at position 136 severely perturb the RNA-binding and splicing capabilities of TDP-43.

It was puzzling that both the acetyl-mimic K136Q and the acetyl-dead K136R substitutions showed the same aggregation-promoting effects. The K136 residue may be in a structurally restrained position not tolerating even conservative amino acid substitutions. Indeed, the NMR structure of the TDP-43 RRMs complexed with RNA[28] revealed that the side chain of K136 is in close apposition to the nucleic acid and the key RNA-binding residues F147/F149 (Fig. 2g). Moreover, K136 is within ≈3Å distance to Q134, L139 and T199, evidently forming a tight RNA-binding configuration that appears not to accommodate the larger guanidinium group of the otherwise conservative K136R substitution.

Introduction of acetyl-lysine (acK) through amber suppression

As K136 turned out to be a very delicate residue for site-directed mutagenesis, it was important to properly validate the pro-aggregative effects for acK136. We succeeded to incorporate authentic acK at the apparently regulatory sites in TDP-43 with amber suppression methodology. TDP-43 mutants were generated with a C-terminal 6xHis tag and an amber stop codon (TAG) substituting the codon at position 84 and at position 136, respectively. Each of these plasmids were co-transfected into $sh^{TDP\text{-}43}$-HEK293E cells, together with a plasmid containing a N-terminally Flag-tagged chimeric acetylated lysine RNA synthetase (AcRS) and four copies of $tRNA_{TAG}$[33]. Together the designed AcRS and the $tRNA_{TAG}$ will incorporate acK added to the media at the introduced amber stop codon, directly incorporating an acetylated lysine site-specifically during the protein translation.

In absence of acK, only truncated forms of TDP-43 were visible due to the introduction of the amber stop codons (Fig. 3a). After adding 5mM acK in the media for 24h, the constructs were translated beyond the amber sites such that full-length TDP-43 including the C-terminal 6xHis tag became detectable, confirming successful amber suppression (Fig. 3a). There was a reduction in the amount of truncated TDP-43 but it did not completely disappear, pointing out the slight inefficiency of the system when compared to endogenous tRNAs. The expression of amber-suppressed full-length mutant TDP-43 was not as high as that from a wtTDP-43 cDNA (Fig. 3a), but still robust. Importantly, [acK84]TDP-43 showed a similar reduction of nuclear import (Fig. 3b) as the K84Q mutant (Fig. 1b), and [acK136]TDP-43 showed the same spotty nuclear distribution (Fig. 3b) as the K136Q mutant (Fig. 1b). To check if the RNA splicing capabilities of TDP-43 were compromised after introducing an acetylated lysine at position 136 in a similar manner to the K136R and K136Q mutants, we performed the *CFTR* minigene assay in sh^{TDP-43}-HEK293E cells. Indeed, [acK136]TDP-43 could only partially rescue *CFTR* exon 9 splicing (Fig. 3c). In addition, we also introduced acetylated lysine at K79 and K121 (Supplementary Fig. 2). As expected from the point mutations (Supplementary Fig. 1), [acK79]TDP-43 and [acK121]TDP-43 did not show any different distribution than wtTDP-43. Taken together, the acetyl-mimic lysine-to-glutamine substitutions did reflect authentic lysine acetylation properties, as confirmed by amber suppression introduction of acK directly.

We were then interested if [acK136]TDP-43 could form aggregates also in the cytoplasm, the most common site where human neuropathological TDP-43 is found[34]. To study this, we disrupted the NLS[6] in the construct ΔNLS-K136$_{TAG}$. [AcK136)TDP-43ΔNLS was uniformly distributed throughout the cytoplasm in most cells. However, there was a fraction of cells developing multiple cytoplasmic aggregates (Fig. 3e,f). Thus, when nuclear import is impaired, K136 acetylation may also promote aggregation of cytosolically mislocalized TDP-43. Next, we deleted the C-terminus in the construct ΔC-K136$_{TAG}$ because the C-terminal low complexity domain mediates LLPS and aggregation of TDP-43 [35]. [acK136)TDP-43ΔC showed a homogeneous nuclear distribution (Fig. 3e,f), confirming that the C-terminal part of TDP-43 plays a crucial role in phase separation and aggregation[21].

FRAP analysis and dynamics of K136 mutant TDP-43 aggregation

As we confirmed that [K136Q]TDP-43 showed the same properties as amber suppressed [acK136]TDP-43, we characterized in greater detail the aggregation process of a C-terminally EGFP-tagged [K136Q]TDP-43 construct. First we measured protein motility in the droplet-like aggregates by fluorescence recovery after photobleaching assay (FRAP). HEK293E cells were transfected with either wtTDP-43-EGFP or [K136Q]TDP-43-EGFP. Then regions of interest (ROI) with bleached for half a second by 488nm laser light irradiation and allowed to recover (Fig. 4a). The wtTDP-43-EGFP showed recovery within a minute after photobleaching (Fig. 4b), consistent with the motility of TDP-43 in the nucleus[20]. By contrast, two types of less mobile pools of [K136Q]TDP-43-EGFP were detected (Fig. 4b). Large [K136Q]TDP-43-EGFP aggregates (ø ≥ 1µm) did not recover for up to 3min recording (Fig. 4b), likely constituting solid aggregates. The smaller aggregates (ø ≤ 0.5µm) showed a significantly slower recovery than the wtTDP-43 with an immobile fraction not recovering at all (Fig. 4B), indicative of LLPS[20].

To investigate the kinetics of LLPS and protein aggregation, we performed long-term live imaging of [K136Q]TDP-43-EGFP. Transfected HEK293E cells were imaged for several hours and the distribution of TDP-43 was monitored. [K136Q]TDP-43 was recorded going into phase separation, forming droplets and these droplets were seen fusing with one another (Fig. 4c and Supplementary Videos 1-3). Together, these results suggest that the aggregation of TDP-43 is a dynamic process from a diffuse distribution to phase separation, eventually towards bigger, immobile aggregates.

Generation of site-specific antibodies against lysine acetylated TDP-43

To study the acetylated forms of TDP-43 in greater detail, we developed rat monoclonal antibodies against acK84 and acK136 TDP-43. Two clones were selected that recognized with high sensitivity their

corresponding amber suppressed TDP-43 targets (Fig. 5a,b) in Western blots, with a very faint band visible in the wtTDP43 lane. The antibodies did not recognize K84R or K136R TDP-43 mutants, respectively. Both antibodies were also capable of detecting the corresponding lysine acetylated forms of TDP-43 by immunofluorescence staining (Fig. 5c,d).

SIRT1 can deacetylate [acK136]TDP-43 and revert its aggregation propensity

The newly generated antibodies allowed us to check for enzymes that could deacetylate [acK136]TDP-43. Given the involvement of sirtuins in neurodegenerative diseases including ALS[36], we obtained clones for all human sirtuins[37]. Flag-tagged SIRT1-7 were co-transfected with $K136_{TAG}$ and the deacetylation effects on amber-suppressed [acK136]TDP-43 were probed with the acetylation-specific antibody. Among the 7 sirtuins, only SIRT1 and SIRT2 strongly reduced [acK136]TDP-43 immunoreactivity (Fig. 6a). To confirm that the reduction in K136 acetylation was truly caused by the deacetylation activity of these sirtuins, we repeated the experiment in the presence of Ex527, a selective Sirt1 and to a lesser extent Sirt2 inhibitor. Indeed, treatment with Ex527 dose-dependently reduced the deacetylation of [acK136]TDP-43 by SIRT1 and SIRT2 (Fig 6b). [AcK136]TDP-43 deacetylation was observed after extreme overexpression of the mainly cytoplasmic NAD+ dependent deacetylase SIRT2[38], so we cannot rule out overexpression artifacts. However, moderate levels of the nuclear deacetylase SIRT1[38] were sufficient to counteract TDP-43 acetylation at K136. It is of note that TDP-43 was reported to bind to the 3'-UTR of SIRT1 mRNA and regulate SIRT1 expression[39]. Thus, the nuclear deacetylase SIRT1 may be engaged in a regulatory network with TDP-43. To see if the reduction of acetylation correlated with a reduction in the amount of aggregates of [acK136]TDP-43, we cotransfected those sirtuins with an impact in TDP-43 acetylation (SIRT1 and SIRT2) as well as other sirtuins with similar level of expression (SIRT3 and SIRT6). When compared to cells without any sirtuin overexpression, SIRT1 and 2 caused a striking reduction in the number of aggregates, even though some level of TDP-43 acetylation was detected (Fig. 6c).

Discussion

In ALS only 4% of familial cases have mutations on TDP-43 and they are even rarer in FTLD (<1%)[40,41]. PTMs of wtTDP-43 might promote disease but it is still unknown if they are a cause or consequence of TDP-43 aggregation[4,17]. Here we show that TDP-43 nuclear import and RNA binding are dynamic processes that can be regulated by distinct PTMs. Specifically, we have discovered that acetylation of the core NLS residue K84 partially reduces nuclear import of TDP-43, leading to the accumulation of cytosolically mislocalized protein, which is considered as an early step of TDP-43 pathogenesis. Moreover, we identify K136 in the RRM1 as a potential regulatory site for TDP-43 RNA binding and splicing activity. Although we could confirm the stippled distribution and reduced *CFTR* splicing activity for the previously reported [K145Q]TDP-43[17,18], the effects for K136 located directly within an essential RRM1 site appeared stronger in our experimental system. Acetylation can modulate the binding to RNA of other hnRNPs and therefore likely for TDP-43 as well[42,43]. Such loss of functional RNA binding may lead to LLPS and eventually the formation of intranuclear TDP-43 aggregates. Acetylation of lysine residues in the RRM1 could trigger aggregation of TDP-43, driving it into phase separated droplets that eventually coalesce into bigger aggregates. When combined with ΔNLS, [acK136]TDP-43 also showed a tendency to form cytosolic aggregates, which are much more commonly found in human patients than intranuclear inclusions[44]. Thus, acetylation of K136 might disengage TDP-43 from functional hnRNP complexes, liberating the protein to unmix into liquid phases. Such LLPS transitions may lead to TDP-43 self-aggregation and the formation of pathological inclusions. The observation that SIRT1 can deacetylate [acK136]TDP-43 indicates that this is a dynamic process that can be regulated in cells. The balance of TDP-43 protein lysine acetyltransferases and deacetylases might determine its physiological functions and when derailed, could lead to LLPS and pathological TDP-43 aggregation in disease. Modulation of this pathway could offer novel therapeutic approaches for the treatment of FTLD and ALS.

The similarities in behaviour between K136R and K136Q TDP-43 mutants were puzzling, suggesting that instead of mimicking the presence or lack of acetylation, the mutants were introducing backbone changes in TDP-43. Point mutagenesis is a broadly used approach to study the cellular effects of protein lysine acetylation but in some cases can fail to rescue protein function[45]. In addition, glutamine and arginine

contain delocalized electrons that are critical for the formation of phase-separated entities[46]. This provides an explanation for the stronger occurrence of phosphorylated aggregates in K136R/Q TDP-43. Amber suppression has its own disadvantages in terms of efficiency and availability of synthetic amino acids, in addition to the possibility of side effects. Transcriptomic analysis of stably amber suppressed cells does not show upregulation of ER stress markers[47]. Another benefit of this approach is the possibility of removing the modification *in vivo* via deacetylases (see Fig. 5).

In our MS analysis we did not detect the previously reported acetylations at K145 and K192 in the RNA-binding domain of TDP-43[17]. Although our experimental setups were similar, perhaps the use of the protein aggregation optimized QBI-293 subclone in their studies made the difference, whereas our study in HEK293E cells revealed acetylation of K121 and K136 in RRM1. Moreover, the MS detection of K145 acetylation was done with ΔNLS mutant TDP-43[17,18] lacking the K84 acetylation site we detected with wtTDP-43. It is possible that differential lysine acetylation events occur in cytosolic and nuclear TDP-43 pools. Antibodies directed against [acK145]TDP-43 stained neuropathological inclusions in ALS but not FTLD-TDP[17]. Yet, MS analysis of TDP-43 PTMs in 2 ALS cases failed to confirm all of these lysine acetylations but instead found K82 acetylation in one ALS case[48]. Unfortunately, the acK136 peptide is poorly immunogenic, and we obtained only one single hybridoma clone that produced antibody with sufficient selectivity and sensitivity for our cell culture experiments, but not for human disease samples (not shown). Thus, the human disease relevance for lysine acetylated TDP-43 remains to be proven.

Materials and Methods

Antibodies

In this study the following antibodies were used for Western blot (WB) and immunofluorescence staining (IF): rat anti-[acK84]TDP-43 (WB, 1:10 supernatant; IF,1:2; this work), rat anti-[acK136]TDP-43 (WB, 1:10 supernatant; IF,1:2; this work; mouse anti-6xHis (WB, 1:10000; IF, 1:1000; Amersham 27-4710-01), rabbit

pan-acetylated lysine (WB, 1:1000; Cell Signalling #9441), rabbit mAb mix pan-acetylated lysine (WB, 1:1000; Ac-K-100, Cell Signalling #9841), mouse anti-Flag HRP-coupled (WB, 1:10000; Sigma #A8592), mouse anti-GAPDH (WB, 1:50000; clone 6C5, Biodesign International #H86504M), rabbit anti-Hsp90 (WB, 1:1000; Cell Signalling #4874), rat anti-[pS409/410]TDP-43 (WB, 1:10; IF, 1:50; clone 1D3), rabbit anti-TDP-43 (WB, 1:8000; IF, 1:1000; ProteinTech 10782-2-AP), mouse anti-TDP-43 (WB, 1:2000; IF, 1:1000; Abnova #H00023435), mouse anti-tubulin (WB, 1:10000; Sigma #T-5168), mouse anti-ubiquitin (WB, 1:4000; Millipore #MAB1510), mouse anti-YY1 (WB, 1:2000; clone H-10, Santa Cruz Biotechnology #7341), mouse anti-β-actin (WB, 1:50000; clone AC-15, Sigma #A5441); rabbit anti-mouse HRP-coupled (WB, 1:10000, Amersham #NIF825); goat anti-rabbit HRP-coupled (WB, 1:10000, Amersham #NIF824); donkey anti-rat HRP-coupled (WB, 1:10000, Jackson Immunoresearch, 712-035-150) and secondary Alexa Fluor 488-, 568-, 647- conjugated antibodies for IF produced in goat were from Invitrogen (1:1000).

cDNA constructs

wtTDP-43 was cloned into pCMV 5'6His (Clontech) via SalI/NotI. Acetyl-mimic glutamine and acetyl-dead arginine substitutions were introduced by site-directed mutagenesis and cloned into pCMV 5'6His (SalI/NotI). The cloning and mutagenesis primers are listed in supplementary table 3. The mutations were introduced via a 2-step PCR mutagenesis, where TDP-43 gene was amplified in two fragments: from the start of the gene to the mutant codon, and from the mutant codon to the end. These two fragments were used as a template for a third PCR reaction in this case amplifying the whole length of TDP-43 and introducing restriction sites at both ends. A detailed version of the protocol is available[49].

For the EGFP tagged constructs, pEGFP c1 wtTDP-43 was used as a template[50]. K136R and K136Q mutations were introduced via site-directed mutagenesis and cloned into pEGFP c1 via BamHI and HindIII.

For the C-terminally tagged amber suppression constructs, TDP-43 was cloned from the pCMV 5' 6His construct previously mentioned into a pCMV 3'6His vector via SalI and Bsd120I. The amber stop codons from constructs K84TAG and K136TAG TDP-43 were introduced via 2-step point mutagenesis. For the N-

terminally tagged amber suppression constructs, TDP-43 was cloned from the amber suppression C-terminally tagged constructs previously mentioned into the vector E400[26] via NheI and BamHI. The plasmids E400_pAS1_4x7SKPylT_EF1_In_IRES_Bsd (E400) (https://benchling.com/s/seq-ZKWKXmPrKBdp8jgpWEt5) and pPB_4xPylT_EF1_IPYE_chAcKRS_Puro (E451) (https://benchling.com/s/seq-6fpczrM3tMNE9fZ0P2nk). Constructs lacking the C-terminal part and with mutated NLS were in addition to K136TAG were cloned from previously described plasmids[6] and cloned into pCMV 3'6His vector via SalI and Bsd120I. Cloning primers are listed in supplementary Table 2.

Plasmids containing sirtuins were ordered from Addgene, and all of them were produced by Eric Verdin. The plasmids ordered were SIRT1 Flag (Addgene plasmid # 13812; RRID:Addgene_13812), SIRT2 Flag (Addgene plasmid # 13813; RRID:Addgene_13813), SIRT3 Flag (Addgene plasmid # 13814; RRID:Addgene_13814), SIRT4 Flag (Addgene plasmid # 13815; RRID:Addgene_13815), SIRT5 Flag (Addgene plasmid # 13816; RRID:Addgene_13816), SIRT6 Flag (Addgene plasmid # 13817; RRID:Addgene_13817), and SIRT7 Flag (Addgene plasmid # 13818; RRID:Addgene_13818). All plasmids were characterised by North et al.[37].

Cell culture and transfections

HEK293E were cultured in Dulbecco's Modified Eagle Medium (DMEM) containing 10% Fetal Bovine Serum (FBS), at 37° C in 5% CO2. Stably TDP-43 Knocked-down cells were generated and characterized by previously[25]. Cells were plated at different concentrations corresponding to the surface of the plate for different experiments. Transfection of plasmids was done 24 hours after plating using FuGENE6 (Promega) at a DNA/FuGENE ratio of 1:4.5 according to manufacturer's instructions.

Amber suppression

HEK293E cells were plated and cultured in DMEM with 10% FBS and transfected with FuGENE6 (Promega) 24 hours later. 24 or 48 hours after transfection the media was substituted with DMEM with 10%FBS and 5mM Nε-Acetyl-L-lysine (A4021, Sigma). Cells were lysed or fixed after being 24 hours in the presence of acetylated lysine. When mentioned, Ex 527 (CAS 49843-98-3, Santa Cruz Biotechnology)

was dissolved in DMSO and added to the cultured cells 24 hours before lysis to a final concentration of 1 or 10µM.

Cell lysis, solubility fractionation, and Western blotting

Cells were collected with a cell scraper and lysed in urea lysis buffer (10mM Tris pH 8, 100mM NaH2PO4, 8M Urea). For the sequential extraction cells were first lysed with RIPA buffer (50mM Tris/HCl pH 8, 150mM NaCl, 1% NP-40, 0.5% Deoxycholate, 0.1% SDS, 10mM NaPPi) with proteinase inhibitor cocktail (Roche). Samples were centrifugated at 18000 rpm for 15 minutes, leaving the RIPA-soluble proteins in the supernatant. The remaining pellet was then lysed in urea buffer, and insoluble material was removed with a centrifugation step at 18000 rpm for 15 minutes. DNA was sheared with a 23-gauge needle. Protein concentration in lysates in urea buffer was quantified with a Bradford Protein assay kit (Biorad) and lysates in RIPA buffer with BCA protein assay kit (Pierce). 3xLaemmli loading buffer with 100mM DTT was added to the samples and afterwards they were boiled at 95° for 5 minutes. The denatured samples were then subjected to Western blot analysis. Denatured samples were loaded and run in polyacrylamide gels. The gels were then blotted using the wet-transfer Trans-Blot® Cell system from Bio-Rad. Proteins were transferred to Hybond-P polyvinylidene difluoride membranes (Millipore). Membranes were blocked with 5% non-fat milk/TBS-T for an hour at room temperature (RT). Primary antibody incubation took place overnight at 4°C. The membranes were washed and incubated with a HRP-coupled secondary antibody for 1-2 hours at RT. Membranes were washed and proteins were detected with Immobilon Western chemiluminescent HRP substrate (Millipore) using the ChemiDoc XRS+ Imaging System.

Generation of monoclonal antibodies against lysine acetylated TDP-43

Rats were immunized with two ovalbumin-coupled synthetic peptides at the same time: one with amino acids corresponding to residues 79-89 of TDP-43, with K84 acetylated (C-KDNKR(Ac)KMDETD); and the second one corresponding to residues 131-141, with K136 acetylated (C-LMVQV(Ac)KKDLKT). Animals were sacrificed and splenocytes were fused with mouse myeloma cells. Hybridoma supernatants were tested for binding to acetylated and non-acetylated peptides by ELISA. Those supernatants that were positive for the acetylated peptides and negative for the non-acetylated peptides were further validated on lysates of cells expressing either wild-type or amber suppressed TDP-43 by Western blot analysis (dilution

1:10) and immunofluorescence staining (dilution 1:2). Hybridoma clones TDACA 9G9 (IgG2c/k) against [acK84]TDP-43 and TDACB 23B3 (IgG1/k) against [acK136]TDP-43 were stably established by limiting dilution cloning.

Immunofluorescence staining

Cells were plated in 6-well plates and grown for 24 hours. They were then transfected and 6 hours after transfection they were transferred (diluted 1:10) to coverslips in a 24-well plate coated with poly-D-lysine (PDL) and collagen. Cells then grew for 72 hours before fixation with 4%PFA/PBS for 20 minutes at RT. Permeabilization of the cell membrane was done with 1% Triton-X-100/PBS for 5 minutes at RT. Blocking was done with 10% Normal Goat Serum in PBS, for 1 hour at RT. The primary antibody incubations were done at the already mentioned concentrations, in 1%BSA/PBS for 2 hours at RT. The secondary antibody incubation was done in 1%BSA/PBS for 1 hour. Mounting was done using 40µl of Dako mounting media per slide, following a 4° incubation overnight. Immunofluorescence images were acquired using a Zeiss fluorescence microscope with Apotome attachment (Axio imager z1 stand).

Fluorescence recovery after photobleaching (FRAP)

HEK293E cells were plated on glass bottom chambered sides (Lab Tek, 154526) coated with PDL and collagen and transfected with C-terminally EGFP-tagged wt or K136Q TDP-43 after 24 hours. Imaging and photobleaching was done with a Zeiss LSM510 META confocal microscope, using a x63/1.4 oil objective. ROIs were bleached for 1s using a 405nm and a 488 nm laser at maximum power output. Cells were continuously imaged for 3 minutes after bleaching. Reference ROIs were measured from unbleached cells to correct for photobleaching due to fluorescence imaging.

Live cell imaging

HEK293E cells were plated on glass bottom chambered slides coated with PDL. They were transfected with C-terminally EGFP-tagged wt or K136Q TDP-43 after 24 hours. While imaging cells were kept in a temperature controlled chamber at 37° with 5%CO_2. Imaging was done with an Axio observer Z1.

LC-MS/MS

Mass spectrometry data were obtained from the analysis of the data generated by Hans et al. [17]. In short, 6xHis tagged TDP-43 was purified via nickel beads pulldown and further purified by size in a SDS-PAGE gel, visualised with Coomasie Brilliant Blue staining. Trypsin (Promega) digestion was performed in-gel. Extracted peptides were analyzed by LC-MS/MS using a nanoflow HPLC system (Ultimate 3000 RSLC; ThermoFisher Scientific) coupled to an Orbitrap Fusion (ThermoFisher Scientific) tandem mass spectrometer. Peptides were separated by reversed C-18 chromatography and 120-min gradients. MS1 spectra were acquired in the Orbitrap at 120,000 resolution. Precursors were selected with the top speed method and 3-s cycle time. HCD-MS2 spectra were acquired with linear ion trap detection. For database search, tandem mass spectra were extracted by MSConvert (ProteoWizard version 3.0.6938). Charge state deconvolution and de-isotoping were not performed. All MS/MS samples were analyzed using Mascot (Matrix Science; version 2.5.1). Mascot was set up to search the SwissProt database (selected for Homo sapiens, 2015_03, 20203 entries) assuming the digestion enzyme trypsin.

RNA-protein pulldown

High performance liquid-chromatography-purified RNA oligonucleotides 5'-(UG)12-3' and 5'-(UC)12-3' were ordered from Sigma. The oligonucleotides were biotinylated using the Pierce RNA 3' End Desthiobiotinylation kit (Cat n° 20163) with small variations. For each 1nmol of biotinylated cytidine bisphosphate 100pmol of RNA were added to the biotinylation reaction. Biotinylated RNA oligos were purified using chloroform:isoamyl. For the RNA-protein pulldown the Pierce Magnetic RNA-Protein Pulldown kit (Cat n° 20164) was used with small variations. Cells were lysed in a NP-40 buffer (50mM NaH2PO4 pH 8.0; 300mM NaCl; 1% NP-40) and 400µg of protein was used for each RNA-protein binding reaction. After 1-hour incubation proteins were eluted in 25µl Laemmli buffer.

Nickel pulldown of 6xHis-tagged TDP-43

Cells were plated in 10cm plates for 24 hours before transfection. 72 hours after transfection cells were lysed in urea lysis buffer containing 10mM imidazole. DNA was sheared with a 23-gauge needle. After quantifying the amount of protein in the lysates with a Bradford Protein assay kit (Biorad), 500-800µg of protein were incubated with Ni-NTA agarose beads (Qiagen) at 4° C overnight. Beads were washed with Urea wash buffer (10mM Tris pH 6.3, 100mM NaH2PO4, 8M Urea) containing 20mM imidazole.

Afterwards proteins were eluted in 3x Laemmli buffer at 95° for 10 minutes. Eluted proteins were analysed in Western blot.

RNA extraction and RT-PCR

sh^{TDP-43} TDP-43 HEK293E cells were plated in 6-well plates and after 24 hours were double-transfected with the corresponding TDP-43 construct and a CFTR minigene construct[12] in a proportion of 2:1. After 72 hours RNA was isolated using the RNeasy Mini Kit (Qiagen) following the indications from the provider. From the isolated RNA cDNA was obtained using the Transcriptor High Fidelity cDNA Synthesis Kit (Sigma) following the protocol of the provider. The cDNA of interest was then amplified via a standard PCR and the product was run in a 2% agarose gel. DNA was visualised using Midori Green from Biozym and the ChemiDoc XRS+ Imaging System.

Statistical analyses

Statistical significance was calculated using Microsoft Excel 2016. P values below 0.01 were considered significant. Unpaired t-tests were performed to compare two variables and assess significance. Chi-squared test was used to assess significance in the immunofluorescence experiments. n values detailed in each figure legend.

Acknowledgements

We would like to thank Dr. Ivana Nikić-Spiegel and Dirk Schwarzer for helpful discussions, Dr. Petra Frick for the validation of the acetyl-TDP-43 antibodies, Dr. Sven Geisler for excellent technical advice, Stefan Hauser for help with Live Cell Imaging and Anna Lechado Terradas for critical comments on the manuscript. This work was supported by the NOMIS Foundation; German Research Foundation (DFG) grant KA1675/3-2; the German Center for Neurodegenerative Diseases (DZNE) within the Helmholtz Association; and the Hertie Foundation.

Author contributions

JGM designed and performed most experiments and analyzed the results. FH assisted the study and provided TDP-43 reagents. FvH and CJG performed MS and analyzed the data. RF generated the antibodies against acetylated TDP-43. SE provided the amber suppression methodology and reagents. AS established the FRAP assay. MN contributed to the study design and provided neuropathological tools. MN and PJK acquired funding. PJK conceptualized and supervised the study. JGM and PJK wrote the draft and all co-authors edited the paper.

Conflict of interest

The authors declare that they have no conflict of interest with the contents of this article.

References

1 Buratti, E. & Baralle, F. E. Vol. 7 420-429 (Taylor and Francis Inc., 2010).

2 Sephton, C. F., Cenik, B., Cenik, B. K., Herz, J. & Yu, G. TDP-43 in central nervous system development and function: clues to TDP-43-associated neurodegeneration. *Biol Chem* **393**, 589-594, doi:10.1515/hsz-2012-0115 (2012).

3 Ratti, A. & Buratti, E. Physiological functions and pathobiology of TDP-43 and FUS/TLS proteins. *J Neurochem* **138 Suppl 1**, 95-111, doi:10.1111/jnc.13625 (2016).

4 Neumann, M. *et al.* Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. *Science* **314**, 130-133, doi:10.1126/science.1134108 (2006).

5 Arai, T. *et al.* TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. *Biochemical and Biophysical Research Communications* **351**, 602-611, doi:10.1016/j.bbrc.2006.10.093 (2006).

6 Winton, M. J. *et al.* Disturbance of nuclear and cytoplasmic TAR DNA-binding protein (TDP-43) induces disease-like redistribution, sequestration, and aggregate formation. *J Biol Chem* **283**, 13302-13309, doi:10.1074/jbc.M800342200 (2008).

7 Pinarbasi, E. S. *et al.* Active nuclear import and passive nuclear export are the primary determinants of TDP-43 localization. *Sci Rep* **8**, 7083, doi:10.1038/s41598-018-25008-4 (2018).

8 Polymenidou, M. *et al.* Long pre-mRNA depletion and RNA missplicing contribute to neuronal vulnerability from loss of TDP-43. *Nat Neurosci* **14**, 459-468, doi:10.1038/nn.2779 (2011).

9 Buratti, E. *et al.* Nuclear factor TDP-43 and SR proteins promote in vitro and in vivo CFTR exon 9 skipping. *EMBO J* **20**, 1774-1784, doi:10.1093/emboj/20.7.1774 (2001).

10 Prasad, A., Sivalingam, V., Bharathi, V., Girdhar, A. & Patel, B. K. The amyloidogenicity of a C-terminal region of TDP-43 implicated in Amyotrophic Lateral Sclerosis can be affected by anions, acetylation and homodimerization. *Biochimie* **150**, 76-87, doi:10.1016/j.biochi.2018.05.003 (2018).

11 Buratti, E. (2018).
12 Gao, F. B., Almeida, S. & Lopez-Gonzalez, R. Dysregulated molecular pathways in amyotrophic lateral sclerosis-frontotemporal dementia spectrum disorder. *EMBO J* **36**, 2931-2950, doi:10.15252/embj.201797568 (2017).
13 Hasegawa, M. *et al.* Phosphorylated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. *Ann Neurol* **64**, 60-70, doi:10.1002/ana.21425 (2008).
14 Neumann, M. *et al.* Phosphorylation of S409/410 of TDP-43 is a consistent feature in all sporadic and familial forms of TDP-43 proteinopathies. *Acta Neuropathol* **117**, 137-149, doi:10.1007/s00401-008-0477-9 (2009).
15 Hans, F., Eckert, M., von Zweydorf, F., Gloeckner, C. J. & Kahle, P. J. Identification and characterization of ubiquitinylation sites in TAR DNA-binding protein of 43 kDa (TDP-43). *J Biol Chem* **293**, 16083-16099, doi:10.1074/jbc.RA118.003440 (2018).
16 Maurel, C. *et al.* A role for SUMOylation in the Formation and Cellular Localization of TDP-43 Aggregates in Amyotrophic Lateral Sclerosis. *Mol Neurobiol* **57**, 1361-1373, doi:10.1007/s12035-019-01810-7 (2020).
17 Cohen, T. J. *et al.* An acetylation switch controls TDP-43 function and aggregation propensity. *Nat Commun* **6**, 5845, doi:10.1038/ncomms6845 (2015).
18 Wang, P., Wander, C. M., Yuan, C. X., Bereman, M. S. & Cohen, T. J. Acetylation-induced TDP-43 pathology is suppressed by an HSF1-dependent chaperone program. *Nat Commun* **8**, 82, doi:10.1038/s41467-017-00088-4 (2017).
19 Maharana, S. *et al.* RNA buffers the phase separation behavior of prion-like RNA binding proteins. *Science* **360**, 918-921, doi:10.1126/science.aar7366 (2018).
20 Mann, J. R. *et al.* RNA Binding Antagonizes Neurotoxic Phase Transitions of TDP-43. *Neuron* **102**, 321-338 e328, doi:10.1016/j.neuron.2019.01.048 (2019).
21 Udan-Johns, M. *et al.* Prion-like nuclear aggregation of TDP-43 during heat shock is regulated by HSP40/70 chaperones. *Hum Mol Genet* **23**, 157-170, doi:10.1093/hmg/ddt408 (2014).
22 Wang, J. *et al.* A Molecular Grammar Governing the Driving Forces for Phase Separation of Prion-like RNA Binding Proteins. *Cell* **174**, 688-699 e616, doi:10.1016/j.cell.2018.06.006 (2018).
23 Bentmann, E. *et al.* Requirements for stress granule recruitment of fused in sarcoma (FUS) and TAR DNA-binding protein of 43 kDa (TDP-43). *J Biol Chem* **287**, 23079-23094, doi:10.1074/jbc.M111.328757 (2012).
24 Zhang, Y. J. *et al.* The dual functions of the extreme N-terminus of TDP-43 in regulating its biological activity and inclusion formation. *Hum Mol Genet* **22**, 3112-3122, doi:10.1093/hmg/ddt166 (2013).
25 Prasad, A., Bharathi, V., Sivalingam, V., Girdhar, A. & Patel, B. K. Molecular Mechanisms of TDP-43 Misfolding and Pathology in Amyotrophic Lateral Sclerosis. *Front Mol Neurosci* **12**, 25, doi:10.3389/fnmol.2019.00025 (2019).
26 Elsässer, S. J. Vol. 1728 237-245 (Humana Press Inc., 2018).
27 Voigt, A. *et al.* TDP-43-mediated neuron loss in vivo requires RNA-binding activity. *PLoS One* **5**, e12247, doi:10.1371/journal.pone.0012247 (2010).
28 Lukavsky, P. J. *et al.* Molecular basis of UG-rich RNA recognition by the human splicing factor TDP-43. *Nat Struct Mol Biol* **20**, 1443-1449, doi:10.1038/nsmb.2698 (2013).
29 Chiang, C. H. *et al.* Structural analysis of disease-related TDP-43 D169G mutation: linking enhanced stability and caspase cleavage efficiency to protein accumulation. *Sci Rep* **6**, 21581, doi:10.1038/srep21581 (2016).
30 Neumann, M. Molecular neuropathology of TDP-43 proteinopathies. *Int J Mol Sci* **10**, 232-246, doi:10.3390/ijms10010232 (2009).

31 Fiesel, F. C. *et al.* Knockdown of transactive response DNA-binding protein (TDP-43) downregulates histone deacetylase 6. *EMBO J* **29**, 209-221, doi:10.1038/emboj.2009.324 (2010).
32 Buratti, E. & Baralle, F. E. Characterization and functional implications of the RNA binding properties of nuclear factor TDP-43, a novel splicing regulator of CFTR exon 9. *J Biol Chem* **276**, 36337-36343, doi:10.1074/jbc.M104236200 (2001).
33 Bryson, D. I. *et al.* Continuous directed evolution of aminoacyl-tRNA synthetases. *Nat Chem Biol* **13**, 1253-1260, doi:10.1038/nchembio.2474 (2017).
34 Kawakami, I., Arai, T. & Hasegawa, M. The basis of clinicopathological heterogeneity in TDP-43 proteinopathy. *Acta Neuropathologica* **138**, 751-770, doi:10.1007/s00401-019-02077-x (2019).
35 Conicella, A. E., Zerze, G. H., Mittal, J. & Fawzi, N. L. ALS Mutations Disrupt Phase Separation Mediated by α-Helical Structure in the TDP-43 Low-Complexity C-Terminal Domain. *Structure* **24**, 1537-1549, doi:10.1016/j.str.2016.07.007 (2016).
36 Tang, B. L. Vol. 37 1147-1160 (Springer New York LLC, 2017).
37 North, B. J., Marshall, B. L., Borra, M. T., Denu, J. M. & Verdin, E. The Human Sir2 Ortholog, SIRT2, Is an NAD+-Dependent Tubulin Deacetylase. *Molecular Cell* **11**, 437-444, doi:10.1016/s1097-2765(03)00038-8 (2003).
38 Seto, E. & Yoshida, M. Erasers of histone acetylation: the histone deacetylase enzymes. *Cold Spring Harb Perspect Biol* **6**, a018713, doi:10.1101/cshperspect.a018713 (2014).
39 Yu, Z. *et al.* Neurodegeneration-associated TDP-43 interacts with fragile X mental retardation protein (FMRP)/Staufen (STAU1) and regulates SIRT1 expression in neuronal cells. *J Biol Chem* **287**, 22560-22572, doi:10.1074/jbc.M112.357582 (2012).
40 Renton, A. E., Chio, A. & Traynor, B. J. State of play in amyotrophic lateral sclerosis genetics. *Nat Neurosci* **17**, 17-23, doi:10.1038/nn.3584 (2014).
41 Baizabal-Carvallo, J. F. & Jankovic, J. Vol. 12 175-185 (Nature Publishing Group, 2016).
42 Gal, J. *et al.* The Acetylation of Lysine-376 of G3BP1 Regulates RNA Binding and Stress Granule Dynamics. *Mol Cell Biol* **39**, doi:10.1128/MCB.00052-19 (2019).
43 Zhang, W., Sun, Y., Liu, W., Dong, J. & Chen, J. SIRT1 mediates the role of RNA-binding protein QKI 5 in the synthesis of triglycerides in non-alcoholic fatty liver disease mice via the PPARalpha/FoxO1 signaling pathway. *Int J Mol Med* **43**, 1271-1280, doi:10.3892/ijmm.2019.4059 (2019).
44 Geser, F., Lee, V. M. & Trojanowski, J. Q. Amyotrophic lateral sclerosis and frontotemporal lobar degeneration: a spectrum of TDP-43 proteinopathies. *Neuropathology* **30**, 103-112, doi:10.1111/j.1440-1789.2009.01091.x (2010).
45 Choudhary, C. *et al.* Lysine acetylation targets protein complexes and co-regulates major cellular functions. *Science* **325**, 834-840, doi:10.1126/science.1175371 (2009).
46 Gomes, E. & Shorter, J. Vol. 294 7115-7127 (American Society for Biochemistry and Molecular Biology Inc., 2019).
47 Elsasser, S. J., Ernst, R. J., Walker, O. S. & Chin, J. W. Genetic code expansion in stable cell lines enables encoded chromatin modification. *Nat Methods* **13**, 158-164, doi:10.1038/nmeth.3701 (2016).
48 Kametani, F. *et al.* Mass spectrometric analysis of accumulated TDP-43 in amyotrophic lateral sclerosis brains. *Sci Rep* **6**, 23281, doi:10.1038/srep23281 (2016).
49 Cormack, B. Directed mutagenesis using the polymerase chain reaction. *Curr Protoc Neurosci* **Chapter 4**, Unit 4 11, doi:10.1002/0471142301.ns0411s03 (2001).
50 Hans, F. *et al.* UBE2E ubiquitin-conjugating enzymes and ubiquitin isopeptidase Y regulate TDP-43 protein ubiquitination. *J Biol Chem* **289**, 19164-19179, doi:10.1074/jbc.M114.561704 (2014).

Figure legends

Figure 1. TDP-43 is acetylated and its acetylation at K84 may affect its nuclear-cytoplasmic trafficking while acetylation at K136 causes a nuclear droplet-like distribution.

a HEK293E cells were transfected with 6xHis tagged TDP-43, which was purified with Ni-NTA beads and subjected to MS. The residues marked in the domain structure of TDP-43 were found to be acetylated (black arrows). K145 has been reported to be acetylated in the literature but we could not find it in our study (grey arrow). **b)** Immunostaining of HEK293E cells transfected with 6xHis tagged wtTDP-43, acetyl-dead (K84R, K136R and K145R) or acetyl-mimics (K84Q, K136Q and K145Q). Scale bar represents 10 µm. N =3. **c)** Classification of 6xHis tagged TDP-43 transfected cells from **b)** *** = $p < 0.001$ as measured by Chi squared test. 300 transfected cells per group classified. **d)** Cytoplasmic and nuclear fractions from HEK293E cells transfected with 6xHis tagged wt, K84R, K84Q or Flag tagged ΔNLS TDP-43. These fractions were analyzed by Western blot. N =3. Hsp90 and YY1 were used as cytoplasmic and nuclear markers respectively.

Figure 2. K136 mutations reduce the solubility of TDP-43 and trigger its ubiquitination and pathological phosphorylation.

a) Sh^{TDP-43}-HEK293E cells were transfected with 6xHis tagged TDP-43 (wt, K136R and K136Q) or Flag-tagged FFLL TDP-43. RIPA soluble and insoluble fractions were separated and analyzed by Western blotting. N =3. **b)** Sh^{TDP-43}-HEK293E cells were transfected with 6xHis tagged TDP-43 (wt, K136R and K136Q). Proteasome activity was inhibited by treatment with 20 µM MG-132 for 6h, which caused wtTDP-43 ubiquitination (lane 3). 6xHis tagged TDP-43 was purified with Ni-NTA beads and analyzed on Western blots. N =3. **c)** Transfected sh^{TDP-43}-HEK293E cells were double immunostained for TDP-43 and phosphorylated TDP-43 (S409/410). Scale bar represents 10µm. **d)** Sh^{TDP-43}-HEK293E cells were

transfected with an empty plasmid, wt or K136Q TDP-43. The lysates were then incubated with biotinylated (UC)12 or (UG)12 RNA oligomeres. Protein-RNA mix was incubated with magnetic streptavidin beads. Bound proteins were eluted and analyzed by Western blotting. **e)** Sh^{TDP-43}-HEK293E cells were cotransfected with the specified TDP-43 constructs and a plasmid containing the *CFTR* minigene. RNA was extracted and splicing of *CFTR* exon 9 was assessed via rtPCR (upper panel). Protein levels are shown in the lower panel. N = 3. **f)** Quantification of 3 replicates looking at the effect of mutations at different lysines of TDP-43 on the splicing of *CFTR* exon 9. ** = $p < 0.01$. **g)** Structure (PDB: 4BS2) of the TDP-43 RNA-binding domain in contact with RNA (blue) with K136 highlighted in the center. Amino acid side chains in the vicinity of K136 and a guanine (Gua) nucleotide of bound RNA are labeled.

Figure 3. Amber suppression-mediated acetylation at K136 of TDP-43 prevents *CFTR* splicing, triggers the formation of nuclear droplets via its C-terminal domain. Acetylation at K84 reduces nuclear import.

a) HEK293E cells cotransfected with a plasmid containing acKRS and $4xtRNA_{TAG}$ (E451) and with TDP-43 with an amber stop codon at different positions and a C-terminal 6xHis tag. Media was changed to 5mM acK-containing media 24 hours before lysis. Protein lysates were analysed via Western blot. **b)** Cells were cotransfected with the E451 plasmid and different C-terminally 6xHis tagged TDP-43 constructs containing amber suppression codons. Cells were fixed after 24h in the presence of 5mM acK. Scale bar represents 10µm. **c)** Sh^{TDP-43}-HEK293E cells cotransfected with E451, *CFTR* minigene, and an empty plasmid, wt or $K136_{TAG}$ TDP-43. After 24 hours in the presence of 5mM acK, RNA was extracted and the splicing of *CFTR* exon 9 was assessed via rtPCR and visualised in an agarose gel. **d)** Sh^{TDP-43}-HEK293E cells were cotransfected with E451 plasmid and different C-terminally tagged TDP-43 constructs. Lanes 3-5 have an amber stop codon at position 136 in addition to a mutated NLS, an amber stop codon at position 84 or a deletion of the C-terminus. Cells were treated with 5mM acK for 24h before lysis. **e)** Sh^{TDP-43}-HEK293E cells were cotransfected with E451 and different C-terminally tagged TDP-43 constructs. Cells were fixed and immunolabeled after 24h in the presence of 5mM acK. Scale bar represents 10µm. **f)** Classification of

250 cells per group cotransfected with E451 plasmid and different 6xHis C-terminally tagged TDP-43 constructs.

Figure 4. [K136Q]TDP-43 droplets have reduced mobility, growing in size and fusing over time.

a) Representative images of FRAP analysis of HEK293 cells transfected with C-terminally EGFP-tagged wt and K136Q TDP-43. Two different groups of [K136Q]TDP-43-EGFP droplets based on size were determined. Time in seconds. Scale Bar represents 5µm. **b)** Quantification of FRAP images. 3 cells quantified per group. **c)** Selected frames from green fluorescence live cell imaging of cells expressing [K136Q]TDP-43-EGFP. Close-up of granules fusing (white arrows). Time in seconds. Scale bar represents 5µm.

Figure 5. Antibodies against acetylated TDP-43 specifically recognize the modified forms.

a-b) Sh^{TDP-43}-HEK293E cells were co transfected with E451 plasmid and different C-terminally 6xHis tagged TDP-43 constructs. After 24h in the presence of 5mM of acK cells were lysed and tagged proteins were purified via Ni-NTA purification. Purified samples were Western probed with antibodies against acetylated K84 and K136 antibodies, respectively. **c-d)** Sh^{TDP-43}-HEK293E cells were co transfected with E451 plasmid and different C-terminally 6xHis tagged TDP-43 constructs. After 24h in the presence of 5mM of acK cells were fixed and immunostained for 6xHis or acetylated TDP-43. Scale bar represents 10µm.

Figure 6. Sirtuins 1 and 2 can deacetylate K136 of TDP-43 and prevent its aggregation.

a) Stably amber suppressed sh^{TDP-43}-HEK293E cells were cotransfected with different sirtuin constructs together with $K136_{TAG}$ TDP-43. Cells were lysed after 24h in the presence of 5mM acK. Protein levels were assessed via Western blot. N =3. **b)** Sh^{TDP-43}-HEK293E cells were cotransfected with E451, $K136_{TAG}$ TDP-43 and Sirtuin 1 or 2. 24h before lysis, 5mM AcK and DMSO or 1µM or 10µM Ex527 containing media was supplied to the cells. **c)** Stably amber suppressed sh^{TDP-43}-HEK293E cells were cotransfected

with different sirtuin constructs together with $K136_{TAG}$ TDP-43. Cells were fixed after 24h in the presence of 5mM acK.

Supplementary Table 1. TDP-43 peptides found by MS to be acetylated. Longer chain lysine modifications like propionylation and butyrylation were not detected.

Supplementary Table 2. List of mutagenesis and cloning primers.

Supplementary Figure 1. Immunostaining of HEK293E cells previously transfected with 6xHis tagged non acetyl-mimics (K79R and K121R) or acetyl-mimics (K79Q and K121Q). Scale bar represents 10 µm. N =3.

Supplementary Figure 2. Amber suppression of TDP-43 at K79 and K121 does not impact its subcellular distribution.

a) Western blot of HEK293E cells transfected with E451 containing a Flag-tagged acKRS, RNA_{TAG} and different C-terminal 6xHis-tagged TDP-43 constructs. Cells were lysed after 24h in the presence of 5mM acK in the media. **b)** Double immunostaining of HEK293E cells transfected with Flag-tagged acKRS, RNA_{TAG} and different C-terminal 6xHis-tagged TDP-43 constructs. Cells were fixed after 24h in the presence of 5mM acK in the media. Scale bar represents 10µm.

Supplementary video 1 and 2. Live imaging of HEK293E cells 48h after transfection with [K136Q]TDP-43-EGFP. Cells were kept at 37°C and 5% CO_2 during the experiment. Imaging took place every 5min for 4h.

Supplementary video 3. Live imaging of HEK293E cells 48h after transfection with [K136Q]TDP-43-EGFP. Cells were kept at 37°C and 5% CO_2 during the experiment. Imaging took place every 2min for 1h.

Figure 1

A
N
NLS
RRM1
RRM2
NES
Low complexity domain
C
78
84
106
176
274
413


B
6xHis
DAPI
Merge
Empty vector
wtTDP-43
K84R
K84Q
K145R
K145Q
K136R
K136Q


C
***
***
***
100%
80%
60%
40%
20%
0%
WT
K79R
K79Q
K84R
K84Q
K121R
K121Q
K136R
K136Q
Nuc. diffuse
Cyt. Diffuse
Nuc. Aggregates
Cyt. aggregates


D
Cyt.
Nuc.
Empty
wtTDP-43
K84R
K84Q
ΔNLS
Empty
wtTDP-43
K84R
K84Q
ΔNLS
kDa
50
100
50
TDP-43
Hsp90
YY1

Figure 2


A
shTDP-43
wtHEK293E
Empty
wtTDP-43
K136R
K136Q
FFLL
kDa
50
37
TDP-43
GAPDH
RIPA
50
37
50
TDP-43
Actin
Urea
B
Input
Empty
wtTDP-43
wt + MG132
K136R
K136Q
kDa
50
25
Ubiquitin
50
TDP-43
50
pTDP-43
37
GAPDH
Pulldown
Empty
wtTDP-43
wt + MG132
K136R
K136Q
150
75
50
Ubiquitin
50
TDP-43
75
pTDP-43
50
C
TDP-43
pTDP-43
DAPI
Merge
Empty
wtTDP-43
K136R
K136Q
D
Input
Empty
wtTDP-43
K136Q
kDa
50
TDP-43
37
GAPDH
Pulldown
-
(UC)12
(UG)12
Empty
wtTDP-43
K136Q
Empty
wtTDP-43
K136Q
Empty
wtTDP-43
K136Q
50
TDP-43
E
shTDP-43
wtHEK293E
Empty
wtTDP-43
K84R
K84Q
K136R
K136Q
K145Q
FFLL
ex 9
CFTR
Actin
kDa
50
TDP-43
37
37
GAPDH
F
Ex. 9 Inc/ex normalised
3
2
1
0
**
**
wt HEK
Ctrl
wtTDP43
K136R
K136Q
FFLL
shTDP-43
G
Gua
T199
L139
F149
Q134
F147

Figure 3


A
Empty
wtTDP-43
K84TAG
K136TAG
AcK
kDa
50
37
37
25
37
Flag
6 His
TDP-43
GAPDH


C
Empty
wtTDP-43
K136TAG
AcK
CFTR
Actin


D
1: Empty 2: wtTDP43 3:ΔNLS
4: K84TAG 5: ΔC-ter
K136TAG
1
2
3
4
5
AcK
kDa
50
50
37
50
37
37
Flag
6 His
TDP-43
GAPDH


B
TDP-43
6 His
DAPI
Merge
Empty -AcK
Empty +AcK
wtTDP-43 -AcK
wtTDP-43 +AcK
K84TAG -AcK
K84TAG +AcK
K136TAG -AcK
K136TAG +AcK


E
TDP-43
6 His
DAPI
Merge
K136TAG
K136TAG ΔCter
ΔNLS
K136TAG ΔNLS


F
% of transfected cells
100%
80%
60%
40%
20%
0%
WT
K136TAG
K136TAG +ΔC-ter
ΔNLS
K136TAG +ΔNLS
Nuc. diffuse
Cyt. diffuse
Nuc. agg.
Cyt. agg.

Figure 4


A
t = -10
t = 0
t = 150
wtTDP-43
K136Q
K136Q
B
WT
≤ 0.5 µm
≥ 1 µm
Normalised fluorescence
Time (sec)
0
0.2
0.4
0.6
0.8
1
0
50
100
150
200
C
t = 0
t = 150
t = 300

Figure 5


A
Input
Pulldown
Empty
wtTDP-43
K136R
K136TAG
kDa
75
50
37
AcK136
TDP-43
GAPDH
B
K84R
K84TAG
AcK84
C
AcK136
6 His
DAPI
Merge
D
AcK84

Figure 6


A
Vec.
Sirt1
Sirt2
Sirt3
Sirt4
Sirt5
Sirt6
Sirt7
kDa
50
AcK136
50
TDP-43
37
50
Flag
37
37
GAPDH


B
Vec.
Sirt1
Sirt1
Sirt1
Sirt2
Sirt2
Sirt2
kDa
-
-
-
Ex527
50
AcK136
37
50
TDP-43
37
37
GAPDH
50
6xHis
37
100
Sirt1
75
50
Sirt2


C
AcK136
6xHis
Flag
DAPI
Merge
K136TAG + Empty
K136TAG + Sirt1
K136TAG + Sirt2
K136TAG + Sirt3
K136TAG + Sirt6